340B Drug Pricing Program
ADAP Advocacy’s 340B Project is centered around patient-centric reforms, deeply rooted in the 1983 Denver Principles’ ethic "Nothing About Us Without Us." The project is anchored by a 35-member patient advisory committee comprised of patients not only living with HIV/AIDS, but also other chronic health conditions and rare—including ankylosing spondylitis, cancer, cystic fibrosis, diabetes, lupus, and Myasthenia Gravis (MG).
BACK TO POLICY CENTERQuick links
Take Action • Blogs • Inforgraphics • Op Eds • Policy Papers • Public Comments • Resources
According to the Health Resources and Services Administration (HRSA), revenues generated by the 340B Drug Pricing Program are intended to be leveraged by healthcare organizations, or what are referred to as covered entities, for the purpose of increasing access to care and treatment for vulnerable patient populations living with conditions that require costly outpatient medications and treatments (United States, Government Accountability Office, 2023). Concerns about the use of those dollars have long existed, particularly regarding reporting requirements and disparate levels of transparency and accountability across covered entities. ADAP Advocacy supports a robust 340B Program, but one that is designed to help patients, rather than a profiteering enterprise for covered entities.
The 340B Project’s work encompasses data collection, policy analysis, videos, and personal stories to shape the organization’s policy priorities surrounding the 340B Program. The centerpiece of this project’s advocacy work is its 340Bmap.org. Hospital revenues and CEO compensation have risen significantly, while hospital charity care has decreased. The map below shows this trend across hospitals, nonprofit health centers, and HIV care sites that serve as covered entities. This map illustrates why patients keep asking, “Is the 340B Program the next ‘Too Big To Fail?’”
Click here to share your thoughts about 340B covered entity transparency on our Discussion Board.
National Oncology Group Realigns 340B Priorities Away from Patient-First
(May 27, 2026)
The American Society of Clinical Oncology (ASCO) released its latest policy position statement on the 340B Drug Pricing Program on May 5th, 2026 (ASCO, 2026). ASCO President, Eric J. Small, MD, FASCO, states, “…reforms focused on eligibility, transparency, and accountability are needed to reflect modern healthcare delivery and to ensure the program continues to benefit the vulnerable people it was designed to help.” But why?
Blogs
View our blogs archive.
BACK TO TOP340B Drug Pricing Program: Too Big To Fail? Charity Care for Poor Patients Plummets
(December 2025)
Congress created the 340B Drug Pricing Program to extend federal resources and improve patient care. The Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, also known as charity care.
INFOGRAPHICS
View our infographics archive.
BACK TO TOP340B Drug Pricing Program: Too Big To Fail? Executive Compensation - Part 2
(November 2025)
The 340B Drug Pricing Program was designed to help poor patients access healthcare services. Yet, despite this program growing to $66 billion, manufacturer rebates are being used to fund excessive compensation for hospital CEOs.
How the 340B Program Lost Its Way
(February 11, 2026)
The 340B Drug Pricing Program was built on a simple idea: hospitals that serve low-income and uninsured patients could buy drugs at a discount and use the savings to help those who can’t afford care.
Op Eds
View our opinion pieces archive.
BACK TO TOPREBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program
(March 2026)
Covered entities, pharmaceutical manufacturers, trade associations, and lobbyists at both the federal and state levels must recall the foundational goal of the federal 340B Drug Pricing Program: to address specific healthcare needs while achieving substantial outcomes. The path forward is not about expansion but about strategic evaluation.
Policy Papers
View our policy papers archive.
BACK TO TOPRE: 340B Rebate Model Pilot [HHS Docket No. HRSA–2025–14619]
(September 8, 2025)
ADAP Advocacy is writing to you to urge you to modify the Health Resources and Services Administration (HRSA) proposed rebate pilot. The HRSA proposal, as it currently stands, is deeply flawed and invites challenge under the Administrative Procedure Act.
Public Comments
RE: Proposed 340B Rebate Model Pilot Program (HHS Docket No. HRSA-2026-03042)
(April 19, 2026)
On behalf of the ADAP Advocacy Association, thank you for the opportunity to submit comments regarding this critically important Request for Information on the proposed rebate model under the 340B Drug Pricing Program.
340B Map
ADAP Advocacy's interactive 340B Map shows trends across hospitals, nonprofit health centers, and HIV care sites that serve as covered entities. This map illustrates why patients keep asking, “Is the 340B Program the next ‘Too Big To Fail?”
Tools
Executive Compensation & Charity Care (Data Sets)
Full Data Analysis - 340B Program Eligibility, Executive Compensation, and Charity Care - Cumulative - (October 2023 - February 2025)
Data Analysis - 340B Program Eligibility, Executive Compensation, and Charity Care - Initial 69 CEs - (October 2023 | July 2024)
Data Analysis - 340B Program Eligibility, Executive Compensation, and Charity Care - Added 33 CEs - (February 2025)
Data Analysis - 340B Program Eligibility, Executive Compensation, and Charity Care - Added 68 CEs - (May 2025 - November 2025)
Fact Sheets